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Non-steroidal anti-inflammatory drugs (NSAIDs) are 
among the drugs most commonly used to reduce 
inflammation and pain. NSAIDs inhibit cyclooxygenase-
2 enzyme  system  results  in  anti-inflammatory  action,  
while  inhibition  of  the  Cox-1 enzyme system results in 
anti-inflammatory action as well as gastric irritation. The 
main factor limiting the oral use of NSAIDs is the 
development of gastrointestinal (GI) adverse events, 
ranging from dyspepsia to serious life-threatening events. 
Several studies have shown the effectiveness of topical 
NSAIDs in treating acute and chronic soft tissue 
conditions. Naproxen sodium [(S)-6-methoxy-alpha-
methyl-2naphthaleneacetic acid sodium salt] is an NSAID 
with analgesic and antipyretic properties used for the 
treatment of musculoskeletal disorders with non-optimal 
characteristics to be delivered through the skin. The 
advantage of a NSAID gel over its oral equivalent is that 
therapeutic benefit can be achieved, while significantly 
reducing any potential systemic side effects. The plasma 
concentration achieved via topical delivery is 1 - 10% of 
that attained by oral medication and therefore has a 
significantly reduced risk of potentially serious side 
effects. Proniosomal Gels  can  resist  the  physiological  
stress caused  by  skin  flexion,  mucociliary  movement,  
adopting  to  the shape  of  the  applied  area  and  for  
controlling  drug  release.  Proniosome, a dry product in 
gel form may avoid many of the problems associated with 
aqueous noisome dispersions and minimize problems of 
physical stability (aggregation, fusion or leaking). 
MATERIALS AND METHODS:  
Materials 
Drug: Naproxen Sodium 
Excipients: Non-ionic surfactants such as span 20, span 
40 & span 60, Lecithin, Cholesterol 
Methods 
Method of Preparation of Naproxen Loaded 
Proniosomal Gel Using Coacervation-Phase 
Separation Technique
17,18,50,51  
Proniosomal gel was prepared by a coacervation-phase 
separation technique. Precisely weighed amounts of 
surfactant, lecithin, cholesterol and drug were taken in a 
clean and dry wide mouthed glass vial of 5.0 ml capacity 
and alcohol (1.0 ml) was added to it. After warming, all 
the ingredients were mixed well with a glass rod; the 
open end of the glass bottle was covered with a lid to 
prevent the loss of solvent from it and warmed over water 
bath at 60-70°C for about 5 min until the surfactant 
mixture was dissolved completely. Then the aqueous 
phase (phosphate buffer saline pH 7.4) was added and 
warmed on a water bath till a clear solution was formed 
which was converted into Proniosomal gel on cooling. 
The gel so obtained was preserved in the same glass 
bottle in dark conditions for characterization. 
Compositions of proniosomal gel formulations are given 




Non-ionic surfactant based Proniosome Gels of naproxen sodium, an cox II inhibitor, were prepared by coacervation phase 
separation method. The prepared systems were characterised for encapsulation efficiency, shape, size and in vitro drug release. 
Stability study was carried out to investigate the leaching of drug from the proniosomal system during storage. The results 
showed that naproxen in all the formulations was successfully entrapped and a substantial change in release rate and an 
alteration in the encapsulation efficiency of naproxen from proniosomes were observed upon varying the type of surfactant and 
cholesterol content. The encapsulation efficiency of proniosomes prepared with Span 40:60 was superior to that prepared with 
all Span prepration . A preparation with Span 40: 60, cholesterol and lecithin gave maximum encapsulation efficiency 
(84.61%) and release results (Q24h= 81%) as compared to other compositions. Proniosomal formulations showed fairly high 
retention of naproxen inside the vesicles at refrigerated temperature (4-8oC) up to 1 month. 
Keywords: Naproxen, proniosomes, Niosomes, encapsulation efficiency, drug delivery. 
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Figure 1: Method of Preparation of Proniosomal Gel 
















pH 7.4 (ml) 
PN1 10 Span 20 1000 100 100 1.0 0.5 
PN2 10 Span 40 1000 100 100 1.0 0.5 
PN3 10 Span 60 1000 100 100 1.0 0.5 
PN4 10 Span 20:Span 40 500:500 100 100 1.0 0.5 
PN5 10 Span 40: Span 60 500:500 100 100 1.0 0.5 
PN6 10 Span 20: Span 60 500:500 100 100 1.0 0.5 
 
Characterization of Proniosomal Gel 
Morphological Evaluation 
A. Physical Appearance50   : The prepared gel was 
viewed by naked eye to characterize color and 
physical state of gel. The appearance  for  each  
formula was  checked  such  as  color, consistency  
and  fluidity  and comparison  of  each  one  with  the 
other. 
B. Optical Microscopic Examination: Hydration of 
proniosomal gel (100mg) was done by adding PBS 7.4 
(5 ml) in a small glass vial  with occasional shaking 
for 10 min. An optical microscope with a camera 
attachment was used to observe the shape of the 
prepared niosomal  vesicles. 
C. Vesicle Size Analysis51 :Size and size distribution 
studies were done for niosomes prepared from 
proniosomes hydration with agitation (shaking) and 
without agitation size Analysis was done by adding 
saline solution (0.9% solution) to the proniosomal gel  
(100mg) in a small glass vial with occasional shaking 
for 10 min. After hydration, the dispersion of 
niosomes was observed under optical microscope 
(Olympus) at 100, 40 and 10x magnification. The 
sizes of 150-200 vesicles were measured using a 
calibrated ocular and stage micrometer fitted in the 
optical microscope  
D. Surface Morphology17,60 : Electron micrographs were 
obtained using scanning electron microscope.  The 
surface morphology (roundness, smoothness and 
formation of aggregates) of proniosomal gel was 
studied by Scanning Electron Microscopy .Hydration 
of proniosomal gel was done similarly as optical 
microscopy. One  drop  of niosomal  suspension  was  
mounted  on  clear glass  slab,  air  dried  and  sputter-
coated  with gold  palladium  (Au/Pd)  using  a  
vacuum evaporator  (Edwards)  and  examined  using  
a scanning  electron microscope   equipped  with  a  
digital camera, at 15 or 20 kV accelerating voltage.   
Determination of pH
14,50,80: The Ph of the Proniosomal 
gels were determined by digital pH meter. One gram of gel 
was dissolved in 25 ml of distilled water and the electrode 
was then dipped in to gel formulation for 30 min until 
constant reading obtained.  And constant reading was 
noted. The measurements of pH of each formulation were 
replicated two times. 
% Encapsulation Efficiency
50
 : The  concentration  of  
drug  entrapped was determined by taking 0.2 g of 
proniosomal gel, weighed  in a glass  tube and added  to 10 
ml of pH  7.4  phosphate  buffer.  The aqueous suspension 
was sonicated in a sonicator bath.  The drug-containing 
Niosomes were separated from untrapped drug by 
centrifugation at 18000 rpm at 5°C for 40 min.  The 
supernatant clear fraction was used  for  the  determination  
of  free  drug and  assayed  for  drug  content.  The 
percentage of drug encapsulation (% EE) was calculated 
by the following equation: 
 
Where, Ct = total concentration of drug, Cf = 
concentration of free drug. 
In Vitro Skin Permeation Studies 
50,51
 
Preparation of Human cadaver skin: The skin was 
stored at 0-4oC after collection.  The excised human 
abdomen skin was treated to remove hair and subdermal 
tissue. The subdermal fat was removed with help of scalpel 
and swapped with isopropyl alcohol. The treated skin was 
stored at 0oC in deep freezer for not more than 2 days. To  
actually  mimic  the  in  vitro  permeation  study,  the  
permeation studies  were  performed  using  excised  
cadaver  skin  mounted  on Franz  cell. The capacity of 
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receptor compartment was 20 ml.  The area of donor 
compartment exposed to receptor compartment was 2.0 
cm2.  The cadaver skin was mounted between the donor 
and receptor compartment.  A weighed amount of 
proniosomal gel equivalent to 10 mg of naproxen was 
placed on one side of the membrane. The receptor medium 
was saline phosphate buffer pH 7.4. The receptor 
compartment was surrounded by a water jacket to maintain 
the temperature at 37±1ºC.  Heat was provided using a 
thermostatic hot plate with a magnetic stirrer. The receptor 
fluid was stirred by a Teflon-coated magnetic bead fitted to 
a magnetic stirrer.  At each  sampling  interval,  (1  ml)  
were withdrawn  and  were  replaced  by  equal  volumes  
of  fresh receptor  fluid  on  each  occasion.  Samples 
withdrawn were analyzed  spectrophotometrically   at  230 
nm. 
Data Analysis via Drug Release Kinetics study
17
 :The 
results of in-vitro release profile obtained for all the 
formulations were plotted in kinetic models as follows, 
1.Cumulative of drug released versus time (zero order 
kinetic model). 2. Log cumulative percent drug remaining 
to be absorbed versus time (First order model) 3. 
Cumulative amount of drug release versus square root of 
time (Higuchi model) 4.  Log cumulative drug released 
versus log time ( Korsmeyer-Peppas model) 
Skin Irritation Test
18:Skin irritation study was performed 
by using  control, standard skin irritant, placebo and test 
placebo niosomal gel. Primary  skin  irritation  test  was  
performed since  skin  is  a vital organ  through which drug  
is  transported. Skin irritation  studies  were  performed  on  
healthy  rabbits  (average  weight:  1.5  to  2.25  kg).  The 
dorsal surface (50 cm2) of  the  rabbits was  cleaned,  and  
the hair was  removed by  shaving. The skin was cleansed 
with  rectified  spirit.  The  best  formulation was  placed 
over  the  skin  and  was  removed  after  24  hrs.  The 
resulting skin reaction was evaluated according to score as 
per Table.   
RESULTS AND DISCUSSION: 
CHARACTERIZATION OF PRONIOSOMAL GEL 
Morphological Evaluation 
A. Physical Appearance: Table shows the color and 
physical state for each formula, these properties are 
differ from each other since they depend on the 
composition. For example, formula PN2 & PN3 gave a 
white semisolid appearance whereas PN1 showed a 
brown liquid, this is due to the property of span 40, 
span 60 and span 20 for each formula respectively. The 
inspection of formula PN4, PN5 and PN6 offered the 
light brownish color with gel state at 37ºC which 
represents the combination of the surfactants cause  a 
change in the physical properties of surfactant after 
mixing and addition of alcohol with a few drops of 
water. 




Colour Physical State 
PN1 Brown Liquid 
PN2 White Semi-solid 
PN3 White Semi-solid 
PN4 Light-brown Gel 
PN5 Light brown Gel 
PN6 Light-brown Gel 
 
B. Optical Microscopic Examination: Hydration of 
proniosomal gel (100mg) was done by adding PBS 7.4 
(5 ml) in a small glass vial with occasional shaking for 
10 min. An optical microscope with a camera 
attachment was used to observe the shape of the 
prepared niosomal  vesicles. 
 
    Formulation – 1                 Formulation – 2               Formulation - 3 
         
Formulation – 4             Formulation – 5            Formulation – 6 
Figure 2: Optical Microscopic Examination of different Proniosomal formulation 
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Vesicle Size Analysis: Determination of vesicle size is 
important for the topical application of vesicles. Size was 
reduced when the dispersion was agitated. The reason for 
this is the energy applied in the agitation which results in 
the breakage of the larger vesicles to smaller vesicles. 
Table 3: Vesicle Size Analysis 
Formulation 
code 






PN1 4.23 1.91 
PN2 3.87 1.75 
PN3 3.05 1.43 
PN4 4.09 1.97 
PN5 3.20 1.66 
PN6 4.15 2.12 
 
Surface Morphology: The morphology of niosomes 
derived from proniosomal gel was studied using Scanning 
Electron Microcopy. SEM revealed that the niosomes 
formed were nearly spherical and homogenous. 
 
Figure 3: Scanning electron image of hydrated 
proniosomal formulation PN5 (magnification 1,000 X) 
Determination of pH: The pH of each formula was 
determined in order to investigate the possibility of any 
side effects in vivo. Due to acidic or alkaline pH which 
may irritate skin .The pH was found between 6.4 and 7.5, 
this range is within the physiologically skin surface pH. 
Changes in the pH are reported to play a role in the 
pathogenesis of skin diseases like irritant contact 
dermatitis and atopic dermatitis. Maintaining the skin‟s pH 
factor helps maintain a proper balance of the “acid mantle” 
which aids in protecting the body from bacteria and helps 
prevent moisture loss. 









% Encapsulation Efficiency: Table.4 shows the effect of 
various sorbitan fatty acid esters and their ratio on the 
encapsulation of Naproxen in proniosomal gel. Naproxen 
was best encapsulated by proniosomal prepared using 
Spans 40 and 60. This might be attributed to fact that 
Spans 40 and 60 are solid at room temperature and showed 
a higher phase transition temperatures [Tc] 
Table 5: % Encapsulation Efficiency 








 (F) In-Vitro Release Study 
Graph 1: Zero order release kinetics Data 
 
 
Graph 2: First Order Release Kinetics Data 
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Drug Release Kinetics with Model Fitting: Calculated 
regression co-efficient for different formulations are 
shown in Table. These values of in-vitro release were 
attempted to fit into various mathematical models, plot of 
zero order, first order, higuchi matrix and peppas. These 
values were compared with each other for model fitting 
equation. Based on the highest regression values (r), the 
bestfit model for PN1, PN2, and PN3 was Zero order and 
for PN4, PN5, and PN6 was Peppas. Further Korsmeyer 
and Peppas equation resulted into the values of n > 1, 
which appears to indicate that the release from the 
prepared microspheres was by Super Case II transport.
 
Table 6: Drug Release Kinetics with Model Fitting 
Formulation  
code 
Correlation coefficient of Model fitting (R
2
) ‘n’ values 
for  Peppas 
Best fit model 
Zero order First order Higuchi matrix Peppas kinetics 
NP1 0.9903 0.9627 0.9508 0.9759 2.2538 Zero Order 
NP2 0.9814 0.8855 0.9298 0.9797 2.2386 Zero Order 
NP3 0.9676 0.8844 0.9044 0.9673 2.2864 Zero Order 
NP4 0.9544 0.8968 0.8822 0.9701 2.2167 Peppas Model 
NP5 0.9497 0.8921 0.8754 0.9668 2.2109 Peppas Model 
NP6 0.9186 0.8467 0.8317 0.9666 2.1168 Peppas Model 
 
Skin irritation studies: The optimized formulation PN5 
showed irritation potential of „0‟, thus proving to be non -
irritant. The „0‟ value in an irritancy test indicates that the 
applied formulations are generally non irritant to human 
skin. No obvious erythema and edema were observed on 
rabbit skin after 24 hr of application of the optimized 
formulation.  Moreover, the optimized formulation is 
composed of phospholipids, a natural component of the 
cell membranes in skin; they act as nonirritating 
moisturizing agents. 
Table 7: Possible score for skin irritation 
TEST SKIN REACTION SCORE 
Erythema 
 
Very slight erythema 0 
Well defined erythema 0 
Moderate to severe erythema 0 
Severe edema 0 
Edema 
Very slight erythema 0 
Well defined erythema 0 
Moderate to severe erythema 0 
Severe edema 0 
 
CONCLUSION:  
In  the  present  study,  an  attempt  will be made  to  
prepare  and  evaluate Naproxen sodium proniosomal gels 
by coacervation-phase separation method for the treatment 
of inflammatory and degenerative disorders of the 
musculoskeletal system. The exhaustive literature survey 
has been done on Vesicle system, Pro-vesicle system, their 
method of preparations, various excipients so that a stable 
Proniosomal formulation of Naproxen sodium can be 
formulated which can release drug for number of hours 
and exhibit  good anti- inflammatory  activity.The 
Transdermal Proniosomal Gels showed controlled drug 
release properties. The results of the present study 
indicated that Naproxen proniosomal gel containing 
lecithin, cholesterol and in combination of surfactants like 
span 20, 40 and 60 produce sustained release of drug over 
a period of 12 hrs for the treatment of inflammatory and 
degenerative disorders of the musculoskeletal system. The 
proniosomal gel could be an effective alternative vehicle 
for delivering the drug through transdermal route to avoid 
side effects associate with oral route. 
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